66O - Outcomes of platinum-sensitive small cell lung cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: a multi-institutional re...

Date 28 March 2014
Event ELCC 2014
Session Proffered papers 4 - SCLC and locally advanced NSCLC
Topics Anti-Cancer Agents & Biologic Therapy
Small-Cell Lung Cancer
Presenter Raffaele Califano
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors R. Califano1, G. Genestreti2, G. Metro3, H. Kenmotsu4, F. Carloni5, M.A. Burgio6, C. Casanova7, M. Tiseo8, E. Scarpi9, T. Korkmaz10
  • 1Department Of Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/UK
  • 2Department Of Medical Oncology, AUSL Rimini, Cervesi Hospital, 47921 - Cattolica/IT
  • 3Oncologia Medica, Azienda Ospedaliera di Perugia S. Maria della Misericordia, Perugia/IT
  • 4Division Of Thoracic Oncology, Shizouka Cancer Center, Shizouka/JP
  • 5Department Of Medical Oncology, AUSL Rimini, “Cervesi” Hospital, Cattolica/IT
  • 6Department Of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola/IT
  • 7Oncology Hematology, Ospedale Sta Maria delle Croci, Ravenna/IT
  • 8Oncologia Medica, Azienda Ospedaliera di Parma, Parma/IT
  • 9Unit Of Biostatistics And Clinical Trials, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.), Meldola/IT
  • 10Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul/TR


Patients with small-cell lung cancer (SCLC) that progress after first-line (FL) chemotherapy have a poor prognosis and second-line (SL) chemotherapy has limited efficacy. Patients relapsing/ progressing > 90 days after completion of FL platinum-based treatment are considered platinum sensitive and could be rechallenged with same treatment. We conducted a multicenter retrospective analysis to evaluate outcomes of SCLC patients who received platinum/etoposide rechallenge as SL.